Integra Lifesciences Hldgs Cp Stock Price, News & Analysis

Integra LifeSciences Holdings Corporation (NASDAQ: IART) announced it will release its first quarter 2022 financial results on April 27, 2022, before the market opens. The management team will host a conference call at 8:30 a.m. ET to discuss the results. Interested parties can access the call by dialing (800)-289-0720 or via a live webcast on the company’s website. A replay will be available until May 7, 2022. Integra specializes in regenerative tissue technologies and neurosurgical solutions, offering a diverse range of high-quality brands.

Integra LifeSciences (Nasdaq: IART) has launched the NeuraGen® 3D Nerve Guide Matrix, a resorbable implant designed to repair peripheral nerve discontinuities. This innovative product combines bovine type 1 collagen with a unique inner matrix featuring porous channels, promoting Schwann cell migration and axonal growth for enhanced recovery after mid-gap nerve repairs. With approximately 50,000 nerve repair procedures performed annually, NeuraGen 3D aims to improve patient outcomes. The launch represents a significant advancement in Integra's peripheral nerve repair portfolio.

Integra LifeSciences Holdings Corporation (NASDAQ: IART) reported its Q4 2021 and full-year results on February 23, 2022. Q4 revenues reached $405.5 million, up 4.3% year-over-year, with GAAP EPS at $0.53, down from $1.09 in Q4 2020. For the full year, revenues were $1,542.4 million, a 12.4% increase, with GAAP EPS rising to $1.98 from $1.57. The company provided 2022 guidance, projecting revenue growth of 2.5% to 3.5% and adjusted EPS between $3.27 and $3.35.

Integra LifeSciences (IART) announced preliminary revenue results for Q4 and full-year 2021, with Q4 revenue expected between $404 million and $406 million, marking a 4% increase year-over-year. Full-year revenue is projected at $1,541 million to $1,543 million, reflecting a 12% increase. The company plans a $125 million share repurchase under an existing $225 million authorization. CEO Jan De Witte expressed optimism about the company's growth strategies, including product launches and international expansion, reaffirming long-term organic growth targets of 5%-7%.

BD (Becton, Dickinson and Company) announced the formation of a nine-person board of directors for Embecta Corp., which will hold BD's Diabetes Care business after the planned spinoff. The board will be led by David F. Melcher and include notable members such as Claire Pomeroy and Christopher R. Reidy. Devdatt Kurdikar will serve as CEO of Embecta. The spinoff is expected to be completed in Q2 2022, pending regulatory approvals. The governance structure includes various committees, and directors will serve staggered terms.

Integra LifeSciences (NASDAQ: IART) reported Q3 2021 revenues of $386.9 million, up 4.5% year-over-year. GAAP diluted EPS increased to $0.51 from $0.38 in 2020, while adjusted EPS rose to $0.86 from $0.80. The company reaffirmed its 2021 revenue guidance of $1,540 million to $1,550 million and raised adjusted EPS guidance to $3.16-$3.20. Cash flow from operations hit $82.8 million, a 18.9% increase. Despite challenges, including COVID-related impacts, Integra showed strong performance in its Codman Specialty Surgical segment, buoyed by new product launches like the CereLink ICP monitor.

Integra LifeSciences Holdings Corporation has appointed Jan D. De Witte as its new President and CEO, succeeding Peter J. Arduini, who is moving to GE Healthcare. De Witte, who has over 30 years of global executive experience in healthcare and technology, previously served as CEO of Barco N.V. and held leading roles at GE. The board expressed confidence in De Witte's ability to drive innovation and stakeholder value. De Witte will officially join the company by the end of the year. This leadership transition comes as Integra aims to enhance its global impact in neurosurgery and regenerative tissue technologies.

Integra LifeSciences Holdings Corporation (NASDAQ: IART) will release its third quarter 2021 financial results on November 2, 2021, before the market opens. A conference call, hosted by management at 8:30 a.m. ET, will discuss the earnings. The call can be accessed at (888) 394-8218 with passcode 7732018, and a webcast will be available on the company’s website. A replay will be accessible until November 12, 2021. Integra specializes in regenerative tissue technologies and neurosurgical solutions, offering a wide range of medical products.

Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leader in medical technology, has announced its participation in two upcoming investor conferences. Carrie Anderson, the executive vice president and CFO, will present at the Wells Fargo 2021 Virtual Healthcare Conference on September 9, 2021, at 11:20 AM ET, and at the Morgan Stanley 19th Annual Global Healthcare Conference on September 13, 2021, at 1:15 PM ET. Interested parties can access the webcasts via the company’s website. Integra specializes in regenerative tissue technologies and neurosurgical solutions.